Related Experiment Video
Updated: Sep 10, 2025
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.0K
Ticagrelor-induced acute isolated thrombocytopenia
Pawan Poddar1, Arvinda Podila1, Majed Abdul Basit Momin2
1Department of Cardiology, Yashoda Hospital, Hyderabad, Telangana, India.
Indian Journal of Pharmacology
|August 22, 2025
Summary
Isolated thrombocytopenia is a rare side effect of ticagrelor, an antiplatelet medication. This case report highlights a patient who developed severe thrombocytopenia after a single ticagrelor dose, with platelet counts recovering after drug discontinuation.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Ticagrelor is a commonly prescribed oral antiplatelet agent.
- Known side effects include bleeding, dyspnea, and bradycardia; severe hematologic reactions are rare.
Observation:
- A 68-year-old male presented with symptoms of acute coronary syndrome.
- Initial laboratory tests, including hemogram, were unremarkable.
- The patient received a single loading dose of ticagrelor.
Findings:
- Severe thrombocytopenia developed rapidly after ticagrelor administration.
- No other potential causes for thrombocytopenia were identified.
- Platelet count normalized after ticagrelor cessation without further intervention.
Implications:
- This case underscores the potential for ticagrelor-induced isolated thrombocytopenia, even with single-bolus dosing.
- Clinicians should consider ticagrelor as a potential cause of unexplained thrombocytopenia in patients on this medication.
- Prompt recognition and discontinuation of ticagrelor can lead to favorable outcomes.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
645
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
645
01:29Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:30Acute Coronary Syndrome I: Introduction
72
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
72
01:16Clot Retraction and Fibrinolysis
6.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.8K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
893
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
893